Efficacy and Safety of Subcutaneous Omalizumab vs Placebo as Add-on Therapy to Corticosteroids for Children and Adults With Asthma A Systematic Review

Departamento de Emergencia, Hospital Central de las Fuerzas Armadas, Av. 8 de Octubre 3020, Montevideo 11600, Uruguay.
Chest (Impact Factor: 7.13). 01/2011; 139(1):28-35. DOI: 10.1378/chest.10-1194
Source: PubMed

ABSTRACT Omalizumab is a humanized monoclonal anti-IgE for the treatment of severe allergic asthma. Because omalizumab targets an immune system molecule, there has been particular interest in the drug's safety.
To establish the efficacy and safety of subcutaneous omalizumab as add-on therapy to corticosteroids, a systematic review of placebo-controlled studies was performed. Primary outcomes were reduction of steroid use and asthma exacerbations. Secondary outcome measures included lung function, rescue medication use, asthma symptoms, health-related quality of life, and adverse effects.
Eight trials (3,429 participants) fulfilled the selection criteria. At the end of the steroid-reduction phase, patients taking omalizumab were more likely to be able to withdraw from corticosteroids completely compared with those taking placebo (relative risk [RR] = 1.80; 95% CI, 1.42-2.28; P = .00001). Omalizumab patients showed a decreased risk of asthma exacerbations at the end of the stable (RR = 0.57; 95% CI, 0.48-0.66; P = .0001) and adjustable-steroid phases (RR = 0.55; 95% CI, 0.47-0.64; P = .0001); post-hoc analysis suggests this effect was independent of duration of treatment, age, severity of asthma, and risk of bias. The frequency of serious adverse effects was similar in the omalizumab (3.8%) and placebo (5.3%) groups. However, injection site reactions were more frequent in the omalizumab patients (19.9% vs 13.2%). There were no indications of increased risk of hypersensitivity reactions, cardiovascular effects, or malignant neoplasms.
Data indicate that the efficacy of add-on omalizumab in patients with moderate-to-severe allergic asthma is accompanied by an acceptable safety profile.

  • Source
    • "For example, asthma is often characterized by increased levels of allergen-mediated immunoglobulin E (IgE) production, which leads to mast cell release of bronchoconstrictive and pro-inflammatory mediators. For a subset of difficult-to-control asthmatics, treatment with an anti-IgE monoclonal antibody, omalizumab, may improve symptoms and reduce asthma flares over time (Rodrigo et al 2011). In contrast, COPD is characterized by progressive breathlessness with exertion often due to dynamic hyperinflation and fixed airflow obstruction. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Asthma and chronic obstructive pulmonary disease (COPD) are distinct but clinically overlapping airway disorders which often create diagnostic and therapeutic dilemmas. Current strategies to discriminate these diseases are limited by insensitivity and poor performance due to biologic variability. We tested the hypothesis that a gas chromatograph/differential mobility spectrometer (GC/DMS) sensor could distinguish between clinically well-defined groups with airway disorders based on the volatile organic compounds (VOCs) obtained from exhaled breath. After comparing VOC profiles obtained from 13 asthma, 5 COPD and 13 healthy control subjects, we found that VOC profiles distinguished asthma from healthy controls and also a subgroup of asthmatics taking the drug omalizumab from healthy controls. The VOC profiles could not distinguish between COPD and any of the other groups. Our results show a potential application of the GC/DMS for non-invasive and bedside diagnostics of asthma and asthma therapy monitoring. Future studies will focus on larger sample sizes and patient cohorts.
    Journal of Breath Research 03/2013; 7(1):017113. DOI:10.1088/1752-7155/7/1/017113 · 3.59 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Allergische Erkrankungen der Lunge können die Atemwege, das Lungenparenchym und die Gefäße der Lunge betreffen. Dazu gehören das exogen-allergische Asthma bronchiale, die exogen-allergische Alveolitis, die allergische bronchopulmonale Aspergillose und das Churg-Strauss-Syndrom. In Bezug auf die Art der allergischen Reaktion und deren pathophysiologische Konsequenzen unterscheiden sich die Krankheitsentitäten stark. Das therapeutische Vorgehen hängt von der vorliegenden Erkrankung ab. In diesem Zusammenhang werden Biologika, die spezifisch und kausal in die Erkrankung eingreifen, zukünftig möglicherweise eine größere Rolle spielen.
    Der Internist 08/2012; 53(8). DOI:10.1007/s00108-012-3059-9 · 0.27 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Die Maßnahmen bei inhalativen Allergien umfassen solche zur Prävention, die Pharmakotherapie mit Antiobstruktiva und antiinflammatorisch wirkenden Substanzen sowie die spezifische Immuntherapie (SIT). Eine weitere Option ist die Therapie mit Omalizumab, die aber nur in schwierigen, nicht anders beherrschbaren Fällen von allergischem Asthma zum Einsatz kommt. Die Vermeidung von Tabakrauchexposition ist die wichtigste und am einfachsten realisierbare Karenzmaßnahme. Die antiinflammatorische Therapie besitzt einen hohen Stellenwert und kommt bereits in Stufe 2 der insgesamt 5 Stufen umfassenden Therapie des Asthma zum Einsatz. Auch bei der Behandlung der allergischen Rhinokonjunktivitis ist der Stellenwert der topischen Kortikoide gestiegen. Die SIT als kausaler Therapieansatz ist bei der allergischen Rhinitis in beiden Applikationsformen effizient, bei Asthma jedoch weniger wirksam. Die Wertigkeit der sublingualen Therapie bei Asthma bronchiale erlaubt noch keine endgültige Beurteilung.
    Der Pneumologe 11/2012; 9(6). DOI:10.1007/s10405-012-0584-0
Show more